The former CEO of Nigeria’s health startup, 54gene, Abasi Ene-Obong, has launched a new startup named, Syndicate Bio.
According to his post on LinkedIn, he stated that Syndicate Bio would spearhead genomics and precision medicine activities in the most varied parts of the world, beginning in Africa.
“After a few months in stealth mode, I am happy to say that we have started Syndicate Bio to empower inclusive advancements in global genomics science.”
Jumi Popoola and Estelle Dogbo, will serve as the chief operational officer and chief scientific officer of Syndicate Bio, respectively.
Ene-Obong also added that Syndicate Bio works in partnership with authorities, pharmaceutical firms, academic institutions, and other stakeholders to advance local precision medicine while building potent datasets that can be applied to drug discovery and development.
In order to address the lack of African genetic material in pharmaceutical research, Ene-Obong launched 54gene in 2019.
He resigned in October 2022 after a difficult year for it. Although the reason for his resignation was not made public, it was implied that it was a reason for investors to provide further funding for the startup.
Over $100 million was knocked off the company’s valuation, and it ultimately had to lay off 30% of its employees.
